Cardiometabolic & kidneyRandomised controlled trial
Cardiovascular Outcomes with Tirzepatide versus Dulaglutide in Type 2 Diabetes
- Randomised controlled trial
- active-comparator-controlled
- double-blind
- noninferiority
Authors' conclusion
Among patients with type 2 diabetes and atherosclerotic cardiovascular disease, tirzepatide was noninferior to dulaglutide with respect to a composite of death from cardiovascular causes, myocardial infarction, or stroke.
Study context
- Population
- Patients with T2DM and atherosclerotic CVD134 excluded
- Participants
- 13,299 patients
- Comparison
- Tirzepatide vs dulaglutide
- Tirzepatiden = 6,586
- Dulaglutiden = 6,579reference
- Primary endpoint
- Composite of:
- CV death
- MI
- Stroke
Primary result
As reported in the abstract
Hazard ratio
0.92
95.3% CI 0.83–1.01
P = 0.003
Events by treatment group
Tirzepatide vs Dulaglutide
HR 0.92 (95.3% CI 0.83–1.01); P = 0.003
Safety
Adverse events
- Incidence of adverse events appeared similar in the two groups; more gastrointestinal adverse events with tirzepatide
Original publication
Cardiovascular Outcomes with Tirzepatide versus Dulaglutide in Type 2 Diabetes. N Engl J Med. Published 18 December 2025. doi:10.1056/nejmoa2505928
Summarised from the published abstract; every number is checked against it